Regulatory Context for Neurological

The practice of neurology in the United States operates within an interconnected web of federal and state authority that governs licensure, device approvals, pharmaceutical use, diagnostic billing, and patient data protection. These frameworks affect every clinical encounter — from the prescribing of antiepileptic drugs to the reimbursement of advanced neuroimaging. Understanding where that authority originates, where it ends, and where it has changed is foundational to interpreting how neurological care is delivered and structured. The home resource for neurological conditions provides broader context for the clinical landscape these regulations shape.

Exemptions and Carve-Outs

Federal regulation of neurological practice does not apply uniformly. Several structural exemptions create meaningful gaps between general medical oversight and specialty-specific control.

The practice of medicine exemption is the most consequential. The Food and Drug Administration (FDA) does not regulate the practice of medicine itself; it regulates drugs, biologics, and devices. Under 21 U.S.C. § 396, the FDA explicitly acknowledges that it does not have authority to regulate how licensed practitioners use approved products. This permits neurologists to prescribe FDA-approved drugs for off-label indications — a routine occurrence in neurology. Botulinum toxin, for instance, is approved for chronic migraine under BLA 103000 but is used off-label for hemifacial spasm, essential tremor, and other movement disorders.

The laboratory-developed test (LDT) exemption has historically allowed hospital-based neurological diagnostic laboratories to develop in-house tests — including certain genetic panels for hereditary neuropathies — without full FDA premarket review, though this carve-out has narrowed following FDA guidance issued since 2014.

Medicare's teaching hospital exception under 42 C.F.R. § 415.172 allows teaching physicians at academic neurology programs to bill for services rendered with a resident's involvement, provided documentation standards are met — a carve-out that shapes how academic neurology departments structure attending supervision.

State scope-of-practice carve-outs also apply. Neuropsychological testing, for example, falls under the licensure authority of psychology boards in states such as California and New York, creating dual-oversight scenarios when neurologists order and neuropsychologists perform cognitive assessments.

Where Gaps in Authority Exist

No single federal agency holds comprehensive jurisdiction over neurological practice, and several areas remain materially underregulated.

Neurotechnology and brain-computer interfaces (BCIs) represent the most prominent regulatory gap. Implantable BCIs fall under FDA Class III device requirements and require Premarket Approval (PMA), but non-invasive consumer-grade EEG headsets marketed for cognitive enhancement exist in a regulatory gray zone, with the Federal Trade Commission (FTC) having primary enforcement authority over deceptive marketing claims rather than clinical safety.

Cerebrospinal fluid (CSF) biomarker testing for Alzheimer's disease — including amyloid-beta and tau assays — has proceeded largely outside standardized regulatory oversight. The Centers for Medicare & Medicaid Services (CMS) coverage for amyloid PET imaging under NCA MCD #CAG-00431R was limited to clinical trials through its 2013 decision, illustrating how coverage policy creates de facto regulatory boundaries where no formal statute governs clinical adoption.

Teleneurology is a second gap area. The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 831) restricts remote prescribing of controlled substances, but many antiepileptic drugs used in neurology — including benzodiazepines — fall under its scope, creating friction for telehealth-based epilepsy management without a separate DEA registration in each patient's state.

How the Regulatory Landscape Has Shifted

The neurological regulatory environment has undergone identifiable structural changes across four domains.

Drug approvals for rare neurological diseases accelerated following the Orphan Drug Act of 1983 (P.L. 97-414), which created tax credits and seven-year market exclusivity. The FDA's Office of Orphan Products Development has designated treatments for amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and Batten disease under this framework.
The 21st Century Cures Act (P.L. 114-255, 2016) altered the approval pathway for medical software and neurostimulation devices, creating the De Novo pathway and exempting certain digital cognitive tools from traditional premarket review. This directly affected software used in neuropsychological screening.
HIPAA's neurological data protections under 45 C.F.R. Parts 160 and 164 apply to neuroimaging data, EEG recordings, and genetic test results held by covered entities. Brain-imaging files qualifying as protected health information (PHI) carry the same breach notification requirements as any other electronic health record, with penalties scaling from $100 to $50,000 per violation under the HITECH Act tiered structure (HHS Office for Civil Rights penalty framework).
CMS reimbursement policy for neurological procedures has shifted through the Physician Fee Schedule (PFS) update process. The 2023 PFS finalized changes to relative value units for electroencephalography and electromyography codes, directly altering practice economics for neurology groups.

Governing Sources of Authority

The primary regulatory sources governing neurological practice in the United States are distributed across federal and state systems.

U.S. Food and Drug Administration (FDA): Drug and device approvals, including neurostimulators, antiseizure medications, and biologics for neurological indications. Authority grounded in the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.).
Centers for Medicare & Medicaid Services (CMS): Coverage determinations, billing codes, and quality reporting under the Merit-based Incentive Payment System (MIPS) affecting neurology practices.
Drug Enforcement Administration (DEA): Scheduling authority for controlled substances used in neurology, including Schedule IV benzodiazepines and Schedule II stimulants used in narcolepsy management.
State Medical Boards: Licensure, disciplinary authority, and scope-of-practice definitions for neurologists. The Federation of State Medical Boards (FSMB) publishes model policy documents that inform but do not bind individual state boards.
The Joint Commission: Accreditation standards for stroke centers, including Primary Stroke Center and Comprehensive Stroke Center certification, which establish care protocols adopted by hospital neurology programs.
American Board of Psychiatry and Neurology (ABPN): Certification standards for neurologists and subspecialists. Board certification, while not federally mandated, is required by most hospital credentialing committees and many payer contracts.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)